发明授权
- 专利标题： Treatment of ophthalmic conditions by selectively removing senescent cells from the eye
-
申请号： US15827539申请日： 2017-11-30
-
公开(公告)号： US10010546B2公开(公告)日： 2018-07-03
- 发明人: Remi-Martin Laberge , Judith Campisi , Marco Demaria , Nathaniel David , Alain Philippe Vasserot , James L. Kirkland , Tamar Tchkonia , Yi Zhu , Darren J. Baker , Bennett G. Childs , Jan M. A. van Deursen
- 申请人： Buck Institute for Research on Aging , Mayo Foundation for Medical Education and Research , Unity Biotechnology, Inc.
- 申请人地址： US CA Brisbane US CA Novato US MN Rochester
- 专利权人： Unity Biotechnology, Inc.,Buck Institute for Research on Aging,Mayo Foundation for Medical Education and Research
- 当前专利权人： Unity Biotechnology, Inc.,Buck Institute for Research on Aging,Mayo Foundation for Medical Education and Research
- 当前专利权人地址： US CA Brisbane US CA Novato US MN Rochester
- 代理机构： Wilson Sonsini Goodrich & Rosati
- 代理商 Michael Schiff
- 主分类号： A61K31/496
- IPC分类号： A61K31/496 ; A61K31/728 ; A61K31/4178 ; A61K9/00
摘要：
Methods are provided herein for selectively killing senescent cells and for treating senescence-associated diseases and disorders by administering a senolytic agent. Senescence-associated diseases and disorders treatable by the methods using the senolytic agents described herein include cardiovascular diseases and disorders associated with or caused by arteriosclerosis, such as atherosclerosis; idiopathic pulmonary fibrosis; chronic obstructive pulmonary disease; osteoarthritis; senescence-associated ophthalmic diseases and disorders; and senescence-associated dermatological diseases and disorders.
公开/授权文献
信息查询
IPC分类:
